MBRX News and Press, Moleculin Biotech Inc.

2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...

Moleculin to Present at the Virtual Investor Pitch Conference PR Newswire Live video webcast on Tuesday, June 18 th at 3:00 PM ET HOUSTON , June 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company...

2024-06-07 17:22:07 ET More on Moleculin Biotech Moleculin Biotech GAAP EPS of -$2.02 Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation Seeking Alpha’s Quant Rating on Moleculin Biotech Read the full article on Seeking A...

Moleculin to Participate in the Virtual Investor Lunch Break Series PR Newswire Live webcast with Walter Klemp , Chairman and Chief Executive Officer, on Wednesday, June 12 th at 12:00 PM ET HOUSTON , June 5, 2024 /PRNewswire/ -- Moleculin...

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress PR Newswire HOUSTON , May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage ...

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) PR Newswire – Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin ...

2024-05-13 11:44:02 ET Moleculin Biotech, Inc. [MBRX] Q1 2024 Earnings Conference Call May 13, 2024, 8:30 a.m. ET Company Participants Walter Klemp - Chairman and CEO Jonathan Foster - EVP and CFO Paul Waymack - Senior CMO Jenene Thomas - IR Conference ...

2024-05-13 07:44:05 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation Moleculin gets U.S. patent issue notification for annamycin targeting unme...

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire – Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1 st an...